The Value of Secondary Neoadjuvant Chemotherapy in Platinum-sensitive Recurrent Ovarian Cancer: a Case-control Study Post GOG-0213 Trial

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2020 Jun 18

PMID 32546257

Authors

Hongyuan Gu

Rui Zhou

Jing Ni

Xia Xu

Xianzhong Cheng

Yan Li

Xiaoxiang Chen

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic value and optimal resection outcome related factors of the secondary cytoreduction surgery (SCR) in Platinum-sensitive recurrent ovarian cancer (PSOC) patients were still in doubt. The present retrospective study aims to determine the relationship between the objective response of secondary neo-adjuvant chemotherapy (SNAC) and the resection outcome of SCR.

Methods: Data were reviewed from 142 type II PSOCs who underwent SCR in Jiangsu Institute of Cancer Research between 1996 and 2016. Among them, 55 cases received preliminary Platinum based SNAC before SCR. Logistic regression analysis was used to explore optimal SCR related factors. Cox proportional hazards model and log-rank test were used to assess the associations between the survival durations and covariates.

Results: Optimal initial CRS (p = 0.02), disappearance of ascites after SNAC (p = 0.04) recurrent status (p = 0.02) and longer Platinum-free interval (p = 0.01) were the independent indicators of optimal SCR. Optimal SCR was associated with time to progression (TTP) but not overall survival (OS) (p = 0.04 and p = 0.41). The TTP and OS of PSOCs underwent SNAC were similar to those patients underwent SCR (p = 0.71, and p = 0.77, respectively) directly.

Conclusions: SNAC might be another choice for PSOCs were not suitable for directly SCR. Optimal SCR had survival benefit in PSOCs whenever underwent SNAC or not.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Eisenkop S, Friedman R, Spirtos N . The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000; 88(1):144-53. DOI: 10.1002/(sici)1097-0142(20000101)88:1<144::aid-cncr20>3.3.co;2-o. View

Berek J, Hacker N, Lagasse L, Nieberg R, Elashoff R . Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol. 1983; 61(2):189-93. View

Munkarah A, Coleman R . Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004; 95(2):273-80. DOI: 10.1016/j.ygyno.2004.09.018. View

van de Laar R, Kruitwagen R, Zusterzeel P, Van Gorp T, Massuger L . Correspondence: Premature Stop of the SOCceR Trial, a Multicenter Randomized Controlled Trial on Secondary Cytoreductive Surgery: Netherlands Trial Register Number: NTR3337. Int J Gynecol Cancer. 2016; 27(1):2. DOI: 10.1097/IGC.0000000000000841. View

Harter P, Heitz F, du Bois A . Surgery for relapsed ovarian cancer: when should it be offered?. Curr Oncol Rep. 2012; 14(6):539-43. DOI: 10.1007/s11912-012-0260-x. View

Zang R, Harter P, Chi D, Sehouli J, Jiang R, Trope C . Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011; 105(7):890-6. PMC: 3185944. DOI: 10.1038/bjc.2011.328. View

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

Wang F, Ye Y, Xu X, Zhou X, Wang J, Chen X . CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res. 2013; 6(1):14. PMC: 3576242. DOI: 10.1186/1757-2215-6-14. View

10.

Scarabelli C, Gallo A, Carbone A . Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001; 83(3):504-12. DOI: 10.1006/gyno.2001.6404. View

11.

Wilson M, Pujade-Lauraine E, Aoki D, Mirza M, Lorusso D, Oza A . Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2016; 28(4):727-732. PMC: 6246494. DOI: 10.1093/annonc/mdw663. View

12.

Del Campo J, Matulonis U, Malander S, Provencher D, Mahner S, Follana P . Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019; 37(32):2968-2973. PMC: 6839909. DOI: 10.1200/JCO.18.02238. View

13.

Zang R, Zhang Z, Li Z, Chen J, Tang M, Liu Q . Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000; 75(1):24-30. DOI: 10.1002/1096-9098(200009)75:1<24::aid-jso5>3.0.co;2-l. View

14.

Coleman R, Spirtos N, Enserro D, Herzog T, Sabbatini P, Armstrong D . Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019; 381(20):1929-1939. PMC: 6941470. DOI: 10.1056/NEJMoa1902626. View

15.

Gungor M, Ortac F, Arvas M, Kosebay D, Sonmezer M, Kose K . The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005; 97(1):74-9. DOI: 10.1016/j.ygyno.2004.11.057. View

16.

Landoni F, Pellegrino A, Cormio G, Milani R, Maggioni A, Mangioni C . Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy. Acta Obstet Gynecol Scand. 1998; 77(2):233-7. View

17.

Matulonis U, Walder L, Nottrup T, Bessette P, Mahner S, Gil-Martin M . Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019; 37(34):3183-3191. PMC: 6881097. DOI: 10.1200/JCO.19.00917. View

18.

OMalley D . New Therapies for Ovarian Cancer. J Natl Compr Canc Netw. 2019; 17(5.5):619-621. DOI: 10.6004/jnccn.2019.5018. View

19.

Xu X, Chen X, Dai Z, Deng F, Qu J, Ni J . Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. J Exp Clin Cancer Res. 2013; 32:61. PMC: 3847054. DOI: 10.1186/1756-9966-32-61. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View